# A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma

> **NCT00660621** · PHASE2 · UNKNOWN · sponsor: **Kentuckiana Cancer Institute** · enrollment: 40 (estimated)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** Temozolomide and Bevacizumab

## Key facts

- **NCT ID:** NCT00660621
- **Lead sponsor:** Kentuckiana Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-04
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2010-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660621, "A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00660621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*